Samsung Biologics has announced plans to acquire Swiss contract development and manufacturing organization (CDMO) PolyPeptide in a transaction valued at 1.46 billion Swiss francs ($1.8 billion).
The proposed offer values PolyPeptide shares at 44.31 Swiss francs ($54.75) each. According to Samsung Biologics, the offer represents a 6% premium to PolyPeptide’s closing share price before the weekend and a 12% premium compared with the company’s volume-weighted average share price over the previous 60 days.
If completed, the transaction would be the largest acquisition ever undertaken by a Korean biopharmaceutical company, according to the Korea JoongAng Daily. The announcement comes eight months after Samsung Biologics agreed to acquire two Human Genome Sciences manufacturing facilities in Rockville, Maryland, from GSK for $280 million as part of efforts to establish its presence in the United States.
PolyPeptide was separated from Ferring Pharmaceuticals 30 years ago and operates a network of active pharmaceutical ingredient manufacturing sites in India, France, Belgium and Sweden, along with two facilities in California. In addition to its headquarters in Switzerland, the company maintains a research and development site in France separate from its manufacturing operations there.
The company employs about 1,400 people and reported revenue of 389 million euros ($439 million) in 2025, an increase of 16% from the previous year. PolyPeptide had previously projected revenue growth of between 20% and 25% for the current year.
Samsung Biologics said the acquisition would expand its capabilities beyond the production of antibodies and antibody-drug conjugates. The company described peptide therapeutics as one of the fastest-growing segments of the biopharmaceutical industry, citing global demand for obesity treatments and the continued development of peptide-based therapies for additional disease areas.
John Rim, chief executive officer of Samsung Biologics, said, “This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1, but by also boosting our geographic reach.”
Founded 15 years ago, Samsung Biologics operates five manufacturing plants across two campuses in Incheon, South Korea, with a combined production capacity of 785,000 liters. A third campus is also under development.
Samsung Biologics expects to launch the offer by the end of August and aims to complete the transaction by the end of the year. Swiss law requires a 30-day review period for merger agreements.
PolyPeptide’s board has unanimously recommended that shareholders accept the offer. Draupnir Holding, which owns more than 55% of PolyPeptide’s shares, also supports the transaction. Earlier this year, after takeover speculation emerged, Draupnir and PolyPeptide’s board said they were reviewing strategic options.
According to PolyPeptide board chair Peter Wilden, the transaction would provide an opportunity to accelerate the company’s strategic objectives, strengthen its position as a global partner for customers and support future growth in peptide-based therapeutics.
Many large pharmaceutical companies outsource peptide production because of the complexity involved in manufacturing these products.
Separately, Samsung Biologics announced in September last year that it had signed a contract manufacturing agreement worth 1.8 trillion Korean won ($1.3 billion) with an unnamed U.S.-based pharmaceutical company. The contract is scheduled to run through 2029.
PolyPeptide is at the center of a proposed $1.8 billion acquisition by Samsung Biologics, marking one of the most significant transactions in the pharmaceutical manufacturing industry. The deal is expected to enhance PolyPeptide’s manufacturing expertise while expanding Samsung Biologics’ capabilities in peptide-based therapeutics.
Why the PolyPeptide Acquisition Matters
The planned acquisition of PolyPeptide aligns with Samsung Biologics’ strategy to broaden its contract development and manufacturing organization (CDMO) services. By integrating PolyPeptide, the company aims to strengthen its position in the rapidly growing peptide therapeutics market and provide customers with a more comprehensive portfolio of manufacturing solutions.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
